Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the effect of subconjunctival Bevacizumab in corneal neovascularization

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asociación para Evitar la Ceguera en México
• Collaborators: National Council of Science and Technology, Mexico; Universidad Nacional Autonoma de Mexico
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

1. Presence of vessels in minimum one quadrant

2. vessels that penetrate more than 0.5 mm of the limb, in any depth

3. who had signed the informed consent

4. those that could attend to frequent ophthalmologic revisions after treatment and could wait for 6 months before the surgical procedure.

Exclusion Criteria:

1. Patients with urgent need of a penetrating keratoplasty, pregnancy or lactancy

2. Patient that may need an additional procedure to penetrating keratoplasty.